Search clinical trials for: Placebo to indacaterol

Total 60701 results

Novartis Pharmaceuticals

Completed

A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device

Asthma

Germany, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol

Persistent Asthma

United States, Netherlands, United Kingdom, France, Germany, Jordan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

China, Australia, India
Novartis

Completed

Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks

Chronic Obstructive Pulmonary Disease

United States
Novartis

Completed

12-week Efficacy of Indacaterol

Chronic Obstructive Pulmonary Disease

United States
Novartis

Completed

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, New Zealand, Belgium
Novartis Pharmaceuticals

Completed

Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma (QAB149)

Asthma

United States
Novartis Pharmaceuticals

Completed

Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma

Asthma

Italy, Germany, France
Novartis Pharmaceuticals

Completed

Indacaterol EfectIveness In COPD Patients With Tuberculosis History (INFINITY)

Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis

Korea, Republic of
Morten Hostrup, PhD

Recruiting

U-LABA/ICS Effects on Exercise Performance, Indacaterol

Exercise Performance

Denmark
Novartis Pharmaceuticals

Completed

Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices

Asthma

Germany, Netherlands, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Different Doses of Indacaterol

Asthma

United States
Novartis

Completed

Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Japan
Novartis
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma

Asthma

France
Novartis

Completed

An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)

Chronic Obstructive Pulmonary Disease

Germany
Novartis Pharmaceuticals

Completed

Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations

Chronic Obstructive Pulmonary Disease

Hong Kong
Yuan-Ming Luo

Completed

Comparison of Tai Chi and Pulmonary Rehabilitation on the Effect of Indacaterol in Treatment naïve COPD Participants

Chronic Obstructive Pulmonary Disease

China
Novartis Pharmaceuticals

Completed

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD) (INTENSITY)

Chronic Obstructive Pulmonary Disease

United States, Spain, Switzerland, France, Italy, Germany, Turkey, Hungary, Norway, Slovakia, Poland, Russian Federation, Canada, Belgium, Austria, Colombia, Denmark, Finland, Greece, Israel, Mexico, United Kingdom
Novartis

Completed

Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control

Chronic Obstructive Pulmonary Disease

Russian Federation, United Kingdom, Spain, Germany, Argentina, Italy, Netherlands, Switzerland, Turkey, France, Czech Republic, Hungary, Slovakia, Peru, Korea, Republic of, Colombia, Israel, Chile, Denmark, Ecuador, Egypt, Estonia, ... and more
Novartis Pharmaceuticals

Completed

To Determine the Relationship Between Baseline Reversibility and the Efficacy of Indacaterol (REVERBREZ)

Chronic Obstructive Pulmonary Disease (COPD)

France
Novartis Pharmaceuticals

Completed

Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Taiwan, Korea, Republic of, Japan, India, Hong Kong, Singapore
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma

Asthma

South Africa, Belgium, Croatia, Turkey, Hungary, Colombia, Slovakia, Philippines, Russian Federation, Guatemala, Germany
Novartis
Schering-Plough

Completed

A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

COPD

France, Germany, Belgium, Italy, Turkey, Hungary, Argentina, Peru, United Kingdom, South Africa, Latvia, Lithuania, Romania, Chile, Ireland, Norway, Poland
Novartis Pharmaceuticals

Completed

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

Asthma

Germany, Spain, United States, Turkey, Canada, Hungary, Slovakia, Italy, Argentina, Czech Republic, France, Peru
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD) (INSIST)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Germany, Spain, Turkey, Hungary, Czech Republic, India, Slovakia
Novartis

Completed

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control

Chronic Obstructive Pulmonary Disease (COPD)

Russian Federation, Germany, Denmark, Italy, Canada, Czech Republic, Hungary, India, Slovakia, France, Colombia, Finland, Taiwan, Iceland, Peru
Novartis

Completed

Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Spain, France
Novartis Pharmaceuticals

Withdrawn

Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control (INITIATE)

Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals
Schering-Plough

Completed

A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent Asthma

Asthma

Russian Federation, United Kingdom, Germany, Spain, Czech Republic, Israel, Poland, South Africa, Belgium, Hungary
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
Novartis Pharmaceuticals

Completed

Cardiac Safety of Indacaterol

Chronic Obstructive Pulmonary Disease | Healthy Volunteers

United States
Novartis Pharmaceuticals

Completed

Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

COPD

United States
Novartis

Completed

Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States, Argentina, Germany, Spain, Canada, India, Turkey, Sweden, Italy
Novartis Pharmaceuticals

Completed

Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.

Asthma

United States
Centro Cardiologico Monzino
Novartis

Completed

Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation

Heart Failure

Italy
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

China
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (GLOW6)

Chronic Obstructive Pulmonary Disease (COPD)

Greece, Belgium, Bulgaria, Turkey, Hungary, Slovakia, Spain, United Kingdom, Russian Federation, Ireland
Novartis Pharmaceuticals

Completed

Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD (INHALE)

Chronic Obstructive Pulmonary Disease

United Kingdom
Novartis

Completed

The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Spain, Belgium, Italy, Canada, Denmark, United States
Novartis

Completed

26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Lung Diseases, Obstructive | Pulmonary Disease, Chronic Obstructive | COPD

United States, Germany, Spain, Argentina, Italy, Turkey, Canada, India, Sweden, Korea, Republic of, Taiwan, Puerto Rico
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease (INTRUST2)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Colombia, Spain, Canada, Slovakia, India, Netherlands, Czech Republic, Hungary
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease (INTRUST1)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Colombia, Argentina, Germany, Spain, Turkey, Guatemala, Mexico, Australia, Denmark, South Africa, Philippines
Novartis

Completed

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Germany, United States, Belgium, Hungary
Novartis

Completed

Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function

Hepatic Insufficiency

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Belgium, Netherlands, Canada, United States
Novartis Pharmaceuticals

Completed

A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Spain, United States, Belgium
Novartis

Completed

Evaluation of Pharmacokinetic Interaction of Indacaterol With Ketoconazole in Healthy Adult Subjects

Healthy

India
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma

Asthma

Germany, Slovakia, Bulgaria, Canada, Poland, Korea, Republic of, Netherlands, Japan
Novartis

Completed

Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and Formoterol

COPD

United Kingdom
AbbVie
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers

Healthy

Japan, Korea, Republic of

Search clinical trials for: Placebo to indacaterol

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations